SMTL ID : 4cni.2 (1 other biounit)

Crystal structure of the Fab portion of Olokizumab in complex with IL- 6

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.20 Å

Oligo State

hetero-1-1-1-mer

Ligands

3 x SO4: SULFATE ION(Non-functional Binders)

SO4.1: 4 residues within 4Å: Chain A: R.27, H.151, R.155, K.158 5 PLIP interactions: 5 interactions with chain A Water bridges: A:K.158, A:K.158 Salt bridges: A:R.27, A:H.151, A:K.158 SO4.2: 3 residues within 4Å: Chain A: P.5, L.6, R.11 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:L.6 Water bridges: A:Q.4 Salt bridges: A:R.11 SO4.4: 2 residues within 4Å: Chain B: E.140, S.141 2 PLIP interactions: 2 interactions with chain B Hydrogen bonds: B:S.141 Water bridges: B:E.140

1 x TAM: TRIS(HYDROXYETHYL)AMINOMETHANE(Non-covalent)

TAM.3: 8 residues within 4Å: Chain B: Y.32, R.100, E.101, S.102, Y.103, Y.104, F.106, S.108 5 PLIP interactions: 5 interactions with chain B Hydrophobic interactions: B:Y.32 Hydrogen bonds: B:R.100, B:E.101, B:Y.103, B:S.108

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Shaw, S. et al., Discovery and Characterization of Olokizumab: A Humanized Antibody Targeting Interleukin-6 and Neutralizing Gp130-Signaling. Mabs (2014)

Release Date

2014-04-30

Peptides

INTERLEUKIN-6: A
OLOKIZUMAB HEAVY CHAIN, FAB PORTION: B
OLOKIZUMAB LIGHT CHAIN, FAB PORTION: C

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

B
H

C
L

INTERLEUKIN-6

OLOKIZUMAB HEAVY CHAIN, FAB PORTION

OLOKIZUMAB LIGHT CHAIN, FAB PORTION

Related Entries With Identical Sequence